Retatrutide, a experimental dual agonist of the GLP-1 binding site and glucose-dependent secreted polypeptide (GIP) target, is demonstrating promising results in early patient studies. Current research https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/